跳至主要内容
临床试验/DRKS00030885
DRKS00030885已完成不适用

CSL964_5003: Benefits of patient self-administration and Respreeza® 4g and 5g vials - an observational study - Benefits of Respreeza self-administration

CSL Behring GmbH0 个研究点目标入组 17 人开始时间: 2022年12月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
17

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Proven diagnosis of AATD, defined as AAT serum level <11 µM (50 mg·dL-1) and/or proteinase inhibitor genotypes ZZ, SZ and compound heterozygotes or homozygotes of other rare deficient variants.
  • - Treated with / or self-administered Respreeza® IV according to current SmPC
  • - Understanding of the study and agreement to give written informed consent.
  • - Able and willing to participate in the study

排除标准

  • - Lack of patient consent

研究者

相似试验